nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—Cytarabine—lymphatic system cancer	0.0472	0.318	CbGbCtD
Trametinib—CYP3A4—Teniposide—lymphatic system cancer	0.0465	0.313	CbGbCtD
Trametinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0326	0.219	CbGbCtD
Trametinib—CYP3A4—Vincristine—lymphatic system cancer	0.0224	0.151	CbGbCtD
Trametinib—Hypokalaemia—Carmustine—lymphatic system cancer	0.00239	0.00281	CcSEcCtD
Trametinib—Dehydration—Vincristine—lymphatic system cancer	0.00233	0.00274	CcSEcCtD
Trametinib—Oedema—Teniposide—lymphatic system cancer	0.00229	0.0027	CcSEcCtD
Trametinib—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00229	0.00269	CcSEcCtD
Trametinib—Anaemia—Fludarabine—lymphatic system cancer	0.00228	0.00268	CcSEcCtD
Trametinib—Infection—Teniposide—lymphatic system cancer	0.00228	0.00268	CcSEcCtD
Trametinib—Dehydration—Mitoxantrone—lymphatic system cancer	0.00227	0.00267	CcSEcCtD
Trametinib—Stomatitis—Bleomycin—lymphatic system cancer	0.00226	0.00266	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00226	0.00265	CcSEcCtD
Trametinib—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00225	0.00264	CcSEcCtD
Trametinib—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00223	0.00262	CcSEcCtD
Trametinib—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00222	0.00261	CcSEcCtD
Trametinib—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00222	0.00261	CcSEcCtD
Trametinib—Leukopenia—Fludarabine—lymphatic system cancer	0.00221	0.0026	CcSEcCtD
Trametinib—Haematuria—Bleomycin—lymphatic system cancer	0.00221	0.0026	CcSEcCtD
Trametinib—Pruritus—Mechlorethamine—lymphatic system cancer	0.0022	0.00259	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.0022	0.00258	CcSEcCtD
Trametinib—Cough—Fludarabine—lymphatic system cancer	0.00216	0.00253	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00215	0.00253	CcSEcCtD
Trametinib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00213	0.0025	CcSEcCtD
Trametinib—Neutropenia—Carmustine—lymphatic system cancer	0.00212	0.00249	CcSEcCtD
Trametinib—Arthralgia—Fludarabine—lymphatic system cancer	0.0021	0.00247	CcSEcCtD
Trametinib—Myalgia—Fludarabine—lymphatic system cancer	0.0021	0.00247	CcSEcCtD
Trametinib—Haemoglobin—Bleomycin—lymphatic system cancer	0.00209	0.00246	CcSEcCtD
Trametinib—Haemorrhage—Bleomycin—lymphatic system cancer	0.00208	0.00245	CcSEcCtD
Trametinib—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00205	0.00241	CcSEcCtD
Trametinib—Neutropenia—Vincristine—lymphatic system cancer	0.00203	0.00238	CcSEcCtD
Trametinib—Oedema—Fludarabine—lymphatic system cancer	0.00202	0.00237	CcSEcCtD
Trametinib—Infection—Fludarabine—lymphatic system cancer	0.002	0.00235	CcSEcCtD
Trametinib—Decreased appetite—Teniposide—lymphatic system cancer	0.00199	0.00234	CcSEcCtD
Trametinib—Renal failure—Carmustine—lymphatic system cancer	0.00199	0.00234	CcSEcCtD
Trametinib—Vomiting—Mechlorethamine—lymphatic system cancer	0.00198	0.00233	CcSEcCtD
Trametinib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00198	0.00232	CcSEcCtD
Trametinib—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00197	0.00232	CcSEcCtD
Trametinib—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00197	0.00232	CcSEcCtD
Trametinib—Stomatitis—Carmustine—lymphatic system cancer	0.00197	0.00232	CcSEcCtD
Trametinib—Urinary tract infection—Carmustine—lymphatic system cancer	0.00197	0.00231	CcSEcCtD
Trametinib—Rash—Mechlorethamine—lymphatic system cancer	0.00196	0.00231	CcSEcCtD
Trametinib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00196	0.0023	CcSEcCtD
Trametinib—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00195	0.00229	CcSEcCtD
Trametinib—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.0019	0.00224	CcSEcCtD
Trametinib—Stomatitis—Vincristine—lymphatic system cancer	0.00188	0.00221	CcSEcCtD
Trametinib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00188	0.0022	CcSEcCtD
Trametinib—Chills—Bleomycin—lymphatic system cancer	0.00187	0.00219	CcSEcCtD
Trametinib—Bone disorder—Methotrexate—lymphatic system cancer	0.00186	0.00218	CcSEcCtD
Trametinib—Renal failure—Mitoxantrone—lymphatic system cancer	0.00185	0.00217	CcSEcCtD
Trametinib—Nausea—Mechlorethamine—lymphatic system cancer	0.00185	0.00217	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00184	0.00217	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00184	0.00216	CcSEcCtD
Trametinib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00183	0.00215	CcSEcCtD
Trametinib—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00183	0.00215	CcSEcCtD
Trametinib—Haemoglobin—Carmustine—lymphatic system cancer	0.00183	0.00215	CcSEcCtD
Trametinib—Haemorrhage—Carmustine—lymphatic system cancer	0.00182	0.00213	CcSEcCtD
Trametinib—Abdominal pain—Teniposide—lymphatic system cancer	0.00181	0.00213	CcSEcCtD
Trametinib—Body temperature increased—Teniposide—lymphatic system cancer	0.00181	0.00213	CcSEcCtD
Trametinib—Erythema—Bleomycin—lymphatic system cancer	0.00181	0.00213	CcSEcCtD
Trametinib—Haematuria—Mitoxantrone—lymphatic system cancer	0.00179	0.00211	CcSEcCtD
Trametinib—Oedema peripheral—Carmustine—lymphatic system cancer	0.00179	0.0021	CcSEcCtD
Trametinib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00179	0.0021	CcSEcCtD
Trametinib—Decreased appetite—Fludarabine—lymphatic system cancer	0.00175	0.00206	CcSEcCtD
Trametinib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00174	0.00205	CcSEcCtD
Trametinib—Fatigue—Fludarabine—lymphatic system cancer	0.00174	0.00204	CcSEcCtD
Trametinib—Constipation—Fludarabine—lymphatic system cancer	0.00172	0.00203	CcSEcCtD
Trametinib—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00172	0.00202	CcSEcCtD
Trametinib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00171	0.00201	CcSEcCtD
Trametinib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0017	0.002	CcSEcCtD
Trametinib—Urethral disorder—Vincristine—lymphatic system cancer	0.0017	0.002	CcSEcCtD
Trametinib—Eye disorder—Carmustine—lymphatic system cancer	0.0017	0.00199	CcSEcCtD
Trametinib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0017	0.00199	CcSEcCtD
Trametinib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00169	0.00198	CcSEcCtD
Trametinib—Anaemia—Bleomycin—lymphatic system cancer	0.00167	0.00197	CcSEcCtD
Trametinib—Asthenia—Teniposide—lymphatic system cancer	0.00165	0.00193	CcSEcCtD
Trametinib—Melaena—Methotrexate—lymphatic system cancer	0.00164	0.00192	CcSEcCtD
Trametinib—Pruritus—Teniposide—lymphatic system cancer	0.00162	0.00191	CcSEcCtD
Trametinib—Arrhythmia—Carmustine—lymphatic system cancer	0.00162	0.00191	CcSEcCtD
Trametinib—Leukopenia—Bleomycin—lymphatic system cancer	0.00162	0.00191	CcSEcCtD
Trametinib—Cardiac disorder—Vincristine—lymphatic system cancer	0.00161	0.00189	CcSEcCtD
Trametinib—Body temperature increased—Fludarabine—lymphatic system cancer	0.00159	0.00187	CcSEcCtD
Trametinib—Mental disorder—Carmustine—lymphatic system cancer	0.00159	0.00187	CcSEcCtD
Trametinib—Erythema—Carmustine—lymphatic system cancer	0.00158	0.00186	CcSEcCtD
Trametinib—Malnutrition—Carmustine—lymphatic system cancer	0.00158	0.00186	CcSEcCtD
Trametinib—Cough—Bleomycin—lymphatic system cancer	0.00158	0.00186	CcSEcCtD
Trametinib—Angiopathy—Vincristine—lymphatic system cancer	0.00157	0.00185	CcSEcCtD
Trametinib—Diarrhoea—Teniposide—lymphatic system cancer	0.00157	0.00184	CcSEcCtD
Trametinib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00156	0.00184	CcSEcCtD
Trametinib—Myalgia—Bleomycin—lymphatic system cancer	0.00154	0.00181	CcSEcCtD
Trametinib—Back pain—Carmustine—lymphatic system cancer	0.00153	0.0018	CcSEcCtD
Trametinib—Mental disorder—Vincristine—lymphatic system cancer	0.00152	0.00179	CcSEcCtD
Trametinib—Chills—Mitoxantrone—lymphatic system cancer	0.00152	0.00178	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00152	0.00178	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—lymphatic system cancer	0.00152	0.00178	CcSEcCtD
Trametinib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00151	0.00177	CcSEcCtD
Trametinib—Vision blurred—Carmustine—lymphatic system cancer	0.00149	0.00175	CcSEcCtD
Trametinib—Oedema—Bleomycin—lymphatic system cancer	0.00148	0.00174	CcSEcCtD
Trametinib—Erythema—Mitoxantrone—lymphatic system cancer	0.00147	0.00173	CcSEcCtD
Trametinib—Infection—Bleomycin—lymphatic system cancer	0.00147	0.00173	CcSEcCtD
Trametinib—Anaemia—Carmustine—lymphatic system cancer	0.00146	0.00172	CcSEcCtD
Trametinib—Back pain—Vincristine—lymphatic system cancer	0.00146	0.00172	CcSEcCtD
Trametinib—Vomiting—Teniposide—lymphatic system cancer	0.00146	0.00171	CcSEcCtD
Trametinib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00145	0.0017	CcSEcCtD
Trametinib—Asthenia—Fludarabine—lymphatic system cancer	0.00145	0.0017	CcSEcCtD
Trametinib—Rash—Teniposide—lymphatic system cancer	0.00145	0.0017	CcSEcCtD
Trametinib—Dermatitis—Teniposide—lymphatic system cancer	0.00145	0.0017	CcSEcCtD
Trametinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00144	0.00169	CcSEcCtD
Trametinib—Headache—Teniposide—lymphatic system cancer	0.00144	0.00169	CcSEcCtD
Trametinib—Pruritus—Fludarabine—lymphatic system cancer	0.00143	0.00168	CcSEcCtD
Trametinib—Back pain—Mitoxantrone—lymphatic system cancer	0.00142	0.00167	CcSEcCtD
Trametinib—Leukopenia—Carmustine—lymphatic system cancer	0.00142	0.00166	CcSEcCtD
Trametinib—Anaemia—Vincristine—lymphatic system cancer	0.0014	0.00164	CcSEcCtD
Trametinib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00139	0.00163	CcSEcCtD
Trametinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00138	0.00162	CcSEcCtD
Trametinib—Hypertension—Carmustine—lymphatic system cancer	0.00137	0.0016	CcSEcCtD
Trametinib—Nausea—Teniposide—lymphatic system cancer	0.00136	0.0016	CcSEcCtD
Trametinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.00136	0.0016	CcSEcCtD
Trametinib—Leukopenia—Vincristine—lymphatic system cancer	0.00135	0.00159	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00135	0.00158	CcSEcCtD
Trametinib—Myalgia—Carmustine—lymphatic system cancer	0.00135	0.00158	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—lymphatic system cancer	0.00132	0.00155	CcSEcCtD
Trametinib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00132	0.00155	CcSEcCtD
Trametinib—Hypertension—Vincristine—lymphatic system cancer	0.0013	0.00153	CcSEcCtD
Trametinib—Oedema—Carmustine—lymphatic system cancer	0.00129	0.00152	CcSEcCtD
Trametinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.00129	0.00151	CcSEcCtD
Trametinib—Myalgia—Vincristine—lymphatic system cancer	0.00129	0.00151	CcSEcCtD
Trametinib—Cough—Mitoxantrone—lymphatic system cancer	0.00128	0.00151	CcSEcCtD
Trametinib—Infection—Carmustine—lymphatic system cancer	0.00128	0.00151	CcSEcCtD
Trametinib—Vomiting—Fludarabine—lymphatic system cancer	0.00128	0.00151	CcSEcCtD
Trametinib—Rash—Fludarabine—lymphatic system cancer	0.00127	0.00149	CcSEcCtD
Trametinib—Dermatitis—Fludarabine—lymphatic system cancer	0.00127	0.00149	CcSEcCtD
Trametinib—Hypertension—Mitoxantrone—lymphatic system cancer	0.00127	0.00149	CcSEcCtD
Trametinib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00126	0.00148	CcSEcCtD
Trametinib—Headache—Fludarabine—lymphatic system cancer	0.00126	0.00148	CcSEcCtD
Trametinib—Myalgia—Mitoxantrone—lymphatic system cancer	0.00125	0.00147	CcSEcCtD
Trametinib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00125	0.00147	CcSEcCtD
Trametinib—Oedema—Vincristine—lymphatic system cancer	0.00123	0.00145	CcSEcCtD
Trametinib—Infection—Vincristine—lymphatic system cancer	0.00122	0.00144	CcSEcCtD
Trametinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.00121	0.00142	CcSEcCtD
Trametinib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00121	0.00142	CcSEcCtD
Trametinib—Oedema—Mitoxantrone—lymphatic system cancer	0.0012	0.00141	CcSEcCtD
Trametinib—Nausea—Fludarabine—lymphatic system cancer	0.0012	0.00141	CcSEcCtD
Trametinib—Infection—Mitoxantrone—lymphatic system cancer	0.00119	0.0014	CcSEcCtD
Trametinib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00119	0.0014	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00118	0.00138	CcSEcCtD
Trametinib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00117	0.00138	CcSEcCtD
Trametinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.00117	0.00137	CcSEcCtD
Trametinib—Insomnia—Carmustine—lymphatic system cancer	0.00117	0.00137	CcSEcCtD
Trametinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00117	0.00137	CcSEcCtD
Trametinib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00116	0.00136	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00112	0.00132	CcSEcCtD
Trametinib—Decreased appetite—Carmustine—lymphatic system cancer	0.00112	0.00132	CcSEcCtD
Trametinib—Insomnia—Vincristine—lymphatic system cancer	0.00111	0.00131	CcSEcCtD
Trametinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00111	0.00131	CcSEcCtD
Trametinib—Constipation—Carmustine—lymphatic system cancer	0.0011	0.0013	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00109	0.00128	CcSEcCtD
Trametinib—Decreased appetite—Vincristine—lymphatic system cancer	0.00107	0.00126	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00106	0.00125	CcSEcCtD
Trametinib—Fatigue—Vincristine—lymphatic system cancer	0.00106	0.00125	CcSEcCtD
Trametinib—Asthenia—Bleomycin—lymphatic system cancer	0.00106	0.00125	CcSEcCtD
Trametinib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00106	0.00124	CcSEcCtD
Trametinib—Constipation—Vincristine—lymphatic system cancer	0.00105	0.00124	CcSEcCtD
Trametinib—Pruritus—Bleomycin—lymphatic system cancer	0.00105	0.00123	CcSEcCtD
Trametinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00104	0.00123	CcSEcCtD
Trametinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.00103	0.00122	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Trametinib—Constipation—Mitoxantrone—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Trametinib—Abdominal pain—Carmustine—lymphatic system cancer	0.00102	0.0012	CcSEcCtD
Trametinib—Body temperature increased—Carmustine—lymphatic system cancer	0.00102	0.0012	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Trametinib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—lymphatic system cancer	0.000983	0.00116	CcSEcCtD
Trametinib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000981	0.00115	CcSEcCtD
Trametinib—Abdominal pain—Vincristine—lymphatic system cancer	0.000974	0.00114	CcSEcCtD
Trametinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000974	0.00114	CcSEcCtD
Trametinib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000949	0.00111	CcSEcCtD
Trametinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000949	0.00111	CcSEcCtD
Trametinib—Vomiting—Bleomycin—lymphatic system cancer	0.00094	0.0011	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000937	0.0011	CcSEcCtD
Trametinib—Infestation—Methotrexate—lymphatic system cancer	0.000937	0.0011	CcSEcCtD
Trametinib—Rash—Bleomycin—lymphatic system cancer	0.000932	0.0011	CcSEcCtD
Trametinib—Dermatitis—Bleomycin—lymphatic system cancer	0.000932	0.00109	CcSEcCtD
Trametinib—Asthenia—Carmustine—lymphatic system cancer	0.000926	0.00109	CcSEcCtD
Trametinib—Renal failure—Methotrexate—lymphatic system cancer	0.000922	0.00108	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—lymphatic system cancer	0.000914	0.00107	CcSEcCtD
Trametinib—Haematuria—Methotrexate—lymphatic system cancer	0.000894	0.00105	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—lymphatic system cancer	0.000884	0.00104	CcSEcCtD
Trametinib—Asthenia—Vincristine—lymphatic system cancer	0.000884	0.00104	CcSEcCtD
Trametinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000883	0.00104	CcSEcCtD
Trametinib—Nausea—Bleomycin—lymphatic system cancer	0.000878	0.00103	CcSEcCtD
Trametinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000861	0.00101	CcSEcCtD
Trametinib—Dizziness—Carmustine—lymphatic system cancer	0.000854	0.001	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000846	0.000994	CcSEcCtD
Trametinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000843	0.00099	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000842	0.000989	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000831	0.000976	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000825	0.000969	CcSEcCtD
Trametinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000821	0.000965	CcSEcCtD
Trametinib—Vomiting—Carmustine—lymphatic system cancer	0.000821	0.000964	CcSEcCtD
Trametinib—Dizziness—Vincristine—lymphatic system cancer	0.000815	0.000957	CcSEcCtD
Trametinib—Rash—Carmustine—lymphatic system cancer	0.000814	0.000956	CcSEcCtD
Trametinib—Dermatitis—Carmustine—lymphatic system cancer	0.000813	0.000955	CcSEcCtD
Trametinib—Headache—Carmustine—lymphatic system cancer	0.000809	0.00095	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000786	0.000924	CcSEcCtD
Trametinib—Vomiting—Vincristine—lymphatic system cancer	0.000783	0.00092	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000781	0.000918	CcSEcCtD
Trametinib—Rash—Vincristine—lymphatic system cancer	0.000777	0.000913	CcSEcCtD
Trametinib—Dermatitis—Vincristine—lymphatic system cancer	0.000776	0.000912	CcSEcCtD
Trametinib—Headache—Vincristine—lymphatic system cancer	0.000772	0.000907	CcSEcCtD
Trametinib—Nausea—Carmustine—lymphatic system cancer	0.000767	0.000901	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—lymphatic system cancer	0.000764	0.000897	CcSEcCtD
Trametinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000763	0.000896	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000758	0.000891	CcSEcCtD
Trametinib—Rash—Mitoxantrone—lymphatic system cancer	0.000757	0.000889	CcSEcCtD
Trametinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000756	0.000888	CcSEcCtD
Trametinib—Chills—Methotrexate—lymphatic system cancer	0.000755	0.000887	CcSEcCtD
Trametinib—Headache—Mitoxantrone—lymphatic system cancer	0.000752	0.000883	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—lymphatic system cancer	0.000737	0.000866	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000733	0.000861	CcSEcCtD
Trametinib—Erythema—Methotrexate—lymphatic system cancer	0.000733	0.000861	CcSEcCtD
Trametinib—Nausea—Vincristine—lymphatic system cancer	0.000732	0.00086	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000717	0.000843	CcSEcCtD
Trametinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000713	0.000837	CcSEcCtD
Trametinib—Back pain—Methotrexate—lymphatic system cancer	0.000709	0.000833	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—lymphatic system cancer	0.00069	0.000811	CcSEcCtD
Trametinib—Anaemia—Methotrexate—lymphatic system cancer	0.000677	0.000795	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—lymphatic system cancer	0.000656	0.00077	CcSEcCtD
Trametinib—Cough—Methotrexate—lymphatic system cancer	0.000639	0.000751	CcSEcCtD
Trametinib—Myalgia—Methotrexate—lymphatic system cancer	0.000624	0.000733	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—lymphatic system cancer	0.000624	0.000733	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000619	0.000728	CcSEcCtD
Trametinib—Infection—Methotrexate—lymphatic system cancer	0.000594	0.000698	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000586	0.000689	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000585	0.000688	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—lymphatic system cancer	0.000581	0.000682	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000578	0.000679	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000545	0.00064	CcSEcCtD
Trametinib—Insomnia—Methotrexate—lymphatic system cancer	0.000541	0.000635	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—lymphatic system cancer	0.00052	0.000611	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000516	0.000606	CcSEcCtD
Trametinib—Fatigue—Methotrexate—lymphatic system cancer	0.000515	0.000606	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000489	0.000574	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000473	0.000555	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000473	0.000555	CcSEcCtD
Trametinib—Asthenia—Methotrexate—lymphatic system cancer	0.000429	0.000504	CcSEcCtD
Trametinib—Pruritus—Methotrexate—lymphatic system cancer	0.000423	0.000497	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000409	0.000481	CcSEcCtD
Trametinib—Dizziness—Methotrexate—lymphatic system cancer	0.000395	0.000464	CcSEcCtD
Trametinib—Vomiting—Methotrexate—lymphatic system cancer	0.00038	0.000447	CcSEcCtD
Trametinib—Rash—Methotrexate—lymphatic system cancer	0.000377	0.000443	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—lymphatic system cancer	0.000377	0.000442	CcSEcCtD
Trametinib—Headache—Methotrexate—lymphatic system cancer	0.000375	0.00044	CcSEcCtD
Trametinib—Nausea—Methotrexate—lymphatic system cancer	0.000355	0.000417	CcSEcCtD
